| abstract |
New useful compounds and pharmaceutical compositions are described as hypocholesterolemic and hypolipidemic agents. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase ("HMG CoA reductase") are described; Methods of using such compounds and compositions for treating subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described. |